Literature DB >> 31855304

Changes in cellular processes occurring in mucopolysaccharidoses as underestimated pathomechanisms of these diseases.

Lidia Gaffke1, Karolina Pierzynowska1, Magdalena Podlacha1, Joanna Brokowska1, Grzegorz Węgrzyn1.   

Abstract

Mucopolysaccharidoses (MPS) are a group of genetic disorders belonging to lysosomal storage diseases. They are caused by genetic defects leading to a lack or severe deficiency of activity of one of lysosomal hydrolases involved in degradation of glycosaminoglycans (GAGs). Partially degraded GAGs accumulate in lysosomes, which results in dysfunctions of cells, tissues, and organs. Until recently, it was assumed that GAG accumulation in cells is the major, if not the only, mechanism of pathogenesis in MPS, as GAGs may be a physical ballast for lysosomes causing inefficiency of cells due to a large amount of a stored material. However, recent reports suggest that in MPS cells there are changes in many different processes, which might be even more important for pathogenesis than lysosomal accumulation of GAGs per se. Moreover, there are many recently published results indicating that lysosomes not only are responsible for degradation of various macromolecules, but also play crucial roles in the regulation of cellular metabolism. Therefore, it appears plausible that previous failures in treatment of MPS (i.e., possibility to correct only some symptoms and slowing down of the disease rather than fully effective management of MPS) might be caused by underestimation of changes in cellular processes and concentration solely on decreasing GAG levels in cells.
© 2019 International Federation for Cell Biology.

Entities:  

Keywords:  cellular processes; glycosaminoglycans; mucopolysaccharidoses; pathomechanisms

Year:  2019        PMID: 31855304     DOI: 10.1002/cbin.11275

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  12 in total

1.  Complex Changes in the Efficiency of the Expression of Many Genes in Monogenic Diseases, Mucopolysaccharidoses, May Arise from Significant Disturbances in the Levels of Factors Involved in the Gene Expression Regulation Processes.

Authors:  Zuzanna Cyske; Lidia Gaffke; Karolina Pierzynowska; Grzegorz Węgrzyn
Journal:  Genes (Basel)       Date:  2022-03-26       Impact factor: 4.141

Review 2.  Ferroptosis and Its Modulation by Autophagy in Light of the Pathogenesis of Lysosomal Storage Diseases.

Authors:  Karolina Pierzynowska; Estera Rintz; Lidia Gaffke; Grzegorz Węgrzyn
Journal:  Cells       Date:  2021-02-10       Impact factor: 6.600

3.  Limited diagnostic facilities impeding the therapeutic approach of Mucopolysaccharidosis in Bangladesh: a case report.

Authors:  Orindom Shing Pulock; Susmita Dey Pinky; Syeda Humaida Hasan
Journal:  J Int Med Res       Date:  2022-06       Impact factor: 1.573

4.  Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy.

Authors:  Francesca Maccari; Laura Rigon; Veronica Mantovani; Fabio Galeotti; Marika Salvalaio; Francesca D'Avanzo; Alessandra Zanetti; Federica Capitani; Orazio Gabrielli; Rosella Tomanin; Nicola Volpi
Journal:  J Mol Med (Berl)       Date:  2022-07-11       Impact factor: 5.606

Review 5.  Mucopolysaccharidosis: A broad review.

Authors:  Ritu Nagpal; Ram Bharos Goyal; K Priyadarshini; Seema Kashyap; Mohita Sharma; Rajesh Sinha; Namrata Sharma
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

6.  Disease burden, management patterns and multidisciplinary clinical approaches for patients with MPS IVA and VI in selected Latin American Countries.

Authors:  Villarreal M Solano; Claudia Yazmín Cossío Mandujano; Carmen Amor Avila-Rejon; Victor Hugo Espin; Hector Paul Quintero Montaño
Journal:  Mol Genet Metab Rep       Date:  2021-05-25

7.  Proteasome Composition and Activity Changes in Cultured Fibroblasts Derived From Mucopolysaccharidoses Patients and Their Modulation by Genistein.

Authors:  Karolina Pierzynowska; Lidia Gaffke; Elżbieta Jankowska; Estera Rintz; Julia Witkowska; Ewa Wieczerzak; Magdalena Podlacha; Grzegorz Węgrzyn
Journal:  Front Cell Dev Biol       Date:  2020-10-20

Review 8.  One drug to treat many diseases: unlocking the economic trap of rare diseases.

Authors:  Karolina Pierzynowska; Teresa Kamińska; Grzegorz Węgrzyn
Journal:  Metab Brain Dis       Date:  2020-09-14       Impact factor: 3.584

9.  Transcriptomic analyses suggest that mucopolysaccharidosis patients may be less susceptible to COVID-19.

Authors:  Karolina Pierzynowska; Lidia Gaffke; Grzegorz Węgrzyn
Journal:  FEBS Lett       Date:  2020-09-06       Impact factor: 3.864

10.  Gene Expression-Related Changes in Morphologies of Organelles and Cellular Component Organization in Mucopolysaccharidoses.

Authors:  Lidia Gaffke; Karolina Pierzynowska; Estera Rintz; Zuzanna Cyske; Izabela Giecewicz; Grzegorz Węgrzyn
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.